A PROPENSITY SCORE-BASED COMPARISON OF TEPOTINIB VERSUS IMMUNOTHERAPY WITH/WITHOUT CHEMOTHERAPY, USING REAL-WORLD DATA IN PREVIOUSLY UNTREATED MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Hook, E. [1 ]
Batteson, R. [2 ]
Christopoulos, P. [3 ,4 ,5 ]
Guisier, F. [6 ,7 ]
Ekman, S. [8 ]
Hatswell, A.
Vioix, H. [9 ]
机构：
[1] Delta Hat Ltd, Nottingham, NGM, England
[2] Delta Hat Ltd, Nottingham, England
[3] Heidelberg Univ Hosp, Thoraxklin, Heidelberg, Germany
[4] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany
[6] Univ Rouen Normandie, Dept Pneumol, LITIS Lab QuantIF team EA4108, CHU Rouen, F-76000 Rouen, France
[7] Inserm CIC CRB 1404, F-76000 Rouen, France
[8] Karolinska Univ Hospital, Dept Oncol Pathol, Karolinska Inst, Stockholm, Sweden
[9] Merck Healthcare KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO168
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [1] Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Reinmuth, N.
    Popat, S.
    Paz-Ares, L.
    Knowles, E.
    Hatswell, A.
    McLean, T.
    Adrian, S.
    Gaumond, B.
    Vioix, H.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S985 - S986
  • [2] TEPOTINIB VERSUS CHEMOTHERAPY IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC): REAL-WORLD EVIDENCE (RWE) AND MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) TO EXPLORE THE IMPACT OF SUBSEQUENT THERAPY
    Wheat, H.
    Hatswell, A.
    Christopoulos, P.
    Ekman, S.
    Guisier, F.
    Hook, E.
    Vioix, H.
    VALUE IN HEALTH, 2023, 26 (12) : S545 - S545
  • [3] Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC)
    Marks, Jennifer Aline
    Gandhi, Nishant
    Halmos, Balazs
    Ramalingam, Suresh S.
    Bazhenova, Lyudmila
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] DEMONSTRATING INTERNAL AND EXTERNAL VALIDITY IN REAL-WORLD DATASETS: A CASE STUDY IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)
    Batteson, R.
    Hook, E.
    Vioix, H.
    Hatswell, A.
    VALUE IN HEALTH, 2022, 25 (12) : S458 - S458
  • [5] Tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Interim analysis of VISION Cohorts A and C
    Griesinger, Frank
    Thomas, Michael
    Reinmuth, Niels
    Wermke, Martin
    Overbeck, Tobias
    Alt, Juergen
    Henschke, Sven
    Wehler, Thomas
    Ochsenreither, Sebastian
    Garassino, Marina Chiara
    Felip, Enriqueta
    Sakai, Hiroshi
    Bruns, Rolf
    Otto, Gordon
    Johne, Andreas
    Paik, Paul K.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 154 - 154
  • [6] Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14)
    Furqan, Muhammad
    Karanth, Siddharth
    Goyal, Ravi K.
    Shih, Yu-Hsuan
    Cai, Beilei
    Rombi, Julien
    Davis, Keith L.
    Caro, Nydia
    Saliba, Teddy Rassem
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib
    Paik, Paul K.
    Yang, Mo
    Knowles, Emma
    Hatswell, Anthony
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [8] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF TEPOTINIB WITH CAPMATINIB IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) WITH MET EXON 14 (METEX14) SKIPPING
    Paik, P.
    Pfeiffer, B.
    Vioix, H.
    Postma, M. J.
    VALUE IN HEALTH, 2022, 25 (12) : S28 - S28
  • [9] MODELING THE COST-EFFECTIVENESS IN A SUBPOPULATION: TEPOTINIB VERSUS CHEMOIMMUNOTHERAPY (C plus IO) IN UNTREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Batteson, R.
    Vioix, H.
    Wheat, H.
    Battershill, W.
    VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [10] VALIDATING THE RESULTS OF A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) IN MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)
    Hatswell, A.
    Batteson, R.
    Hook, E.
    Wheat, H.
    Vioix, H.
    McLean, T.
    Alexopoulos, S.
    Baijal, S.
    VALUE IN HEALTH, 2022, 25 (12) : S21 - S22
12345